Psilocybin in Psychotherapy 2026: Johns Hopkins Research, NEJM, Effectiveness and Legality in Poland

Psilocybin is one of the most promising yet controversial substances in 21st-century psychiatry. The renaissance of clinical research, initiated at Johns Hopkins in 2006, has led to the publication of groundbreaking studies in Nature Medicine, the New England Journal of Medicine, and The Lancet Psychiatry. A review by Leger 2022 indicated that 71% of patients with treatment-resistant depression achieved a clinical response after two sessions of 25 mg psilocybin (Journal of Psychopharmacology, 2022). This is an outcome that cannot be ignored.

This guide has one goal: to separate hard scientific data from media hype and dangerous simplifications. We will discuss the history of psilocybin, its mechanism of action on the 5-HT2A receptor and the default mode network, clinical protocols from Johns Hopkins, Imperial College, and Compass Pathways, key RCTs by Carhart-Harris and Goodwin, safety profiles, specific risks, as well as the legal status in Poland. For Polish readers, we will also present legal mental health support tools: psychotherapy, SSRIs, medical ketamine, CBD, and CBG.

The article is based on research published in Nature Medicine, NEJM, The Lancet Psychiatry, Journal of Psychopharmacology, JAMA Psychiatry, Scientific Reports, as well as reports from the Johns Hopkins Center for Psychedelic and Consciousness Research and MAPS. The author is Michał Waluk, editor of the u Bucha blog, who has been educating about cannabinoids and psychedelic medicine since 2022. We do not provide medical advice and do not promote the use of legally controlled substances in Poland.

What is psilocybin and how was it discovered?

Psilocybin is a tryptamine alkaloid, naturally present in over 200 species of mushrooms from the genera Psilocybe, Panaeolus, and Gymnopilus. Chemically, it is a prodrug: after ingestion, it is rapidly dephosphorylated to psilocin (4-OH-DMT) in the intestine and liver. Albert Hofmann, the same chemist who synthesized LSD, isolated psilocybin and psilocin in 1958 at Sandoz laboratories in Basel (PMC, 2017).

Before chemical identification, psilocybin mushrooms were used by indigenous peoples of Mesoamerica for at least 3000 years. Mazatec healers from Oaxaca, Mexico, including the famous Maria Sabina, used them in rituals called velada. American ethnobotanist R. Gordon Wasson described his encounter with Sabina in Life Magazine in 1957, which opened the mushrooms to Western awareness.

This chapter of history is crucial because it shows that the therapeutic framework of psilocybin is not new. Indigenous healers understood the principle that modern psychiatry calls set-setting-integration: appropriate intention, safe ceremonial environment, working through the experience post-session. The difference lies in laboratory control of dosage, standardization of protocol, and measurable clinical endpoints.

A Brief History of Scientific Research: From Harvard to Johns Hopkins

From 1960 to 1962, Timothy Leary and Richard Alpert conducted the Harvard Psilocybin Project: a series of studies on psilocybin in prisoners, students, and clergy. Controversial experiments led to the expulsion of both researchers from the university in 1963. In 1970, the Controlled Substances Act in the USA placed psilocybin in Schedule I, halting clinical research for over 30 years.

The renaissance began in 2006 when Roland Griffiths at Johns Hopkins published the first study in Psychopharmacology after decades on the effects of mystical experience after psilocybin. 67% of participants reported the experience as 'one of the five most important in their lives' (Psychopharmacology, 2006). This opened doors for further clinical trials at Imperial College London, NYU, UCLA, and Yale.

Pharmacology in a Nutshell: The 5-HT2A Receptor and the Default Mode Network

Psilocin, the active metabolite of psilocybin, primarily acts as a partial agonist of the serotonin receptor 5-HT2A. This receptor is strongly expressed in the pyramidal neurons of layer V of the prefrontal cortex, hippocampus, and amygdala. Its activation destabilizes the so-called Default Mode Network (DMN), a neural network responsible for rumination, the 'self' narrative, and autobiographical thinking.

Carhart-Harris 2017 in Scientific Reports demonstrated via fMRI that psilocybin reduces DMN coherence, which correlates with a reduction in depressive rumination and the phenomenon of 'ego dissolution' (Scientific Reports, 2017). In animal models, Shao 2021 in Neuron showed that a single dose of psilocybin increases dendritic spine density by 10% and raises BDNF for at least 30 days. This is the neurobiological basis for the 'rapid-acting neuroplasticity' hypothesis.

Psilocybin was isolated by Albert Hofmann in 1958 at Sandoz. Its active metabolite, psilocin, acts as a partial agonist of the 5-HT2A receptor and destabilizes the Default Mode Network (Scientific Reports, 2017). In animal models, a single dose increases dendritic spine density by 10% and raises BDNF for at least 30 days (Neuron, 2021).

What are the key clinical studies on psilocybin in depression?

Research on psilocybin in depression is today the most densely populated and well-documented field in psychedelic psychiatry. A meta-analysis by Leger 2022 in the Journal of Psychopharmacology included 7 RCTs with a total of 436 patients and showed an average reduction in the Beck Depression Inventory of 12.2 points compared to 5.1 in the control group (Journal of Psychopharmacology, 2022). The results are consistent across centers and independent laboratories.

The difference between data on psilocybin and typical antidepressant studies is the effect size. Cohen's d in treatment-resistant depression with psilocybin is 1.2-1.8, while for SSRIs it is usually 0.3-0.5. This is a several-fold difference in effect size, although of course with the caveat of smaller samples and difficult blinding due to psychedelic effects.

Carhart-Harris 2021: psilocybin vs escitalopram in Nature Medicine

Robin Carhart-Harris's study from Imperial College London, published in Nature Medicine in April 2021, is the first head-to-head RCT comparing psilocybin with traditional SSRIs in depression (Nature Medicine, 2021). 59 patients were randomly assigned to two arms: psilocybin 25 mg in session 1 and 3 weeks (with placebo escitalopram), or escitalopram 10-20 mg daily for 6 weeks (with placebo psilocybin 1 mg).

Results: the primary endpoint (QIDS-SR-16, self-reported depression) showed a reduction of 8.0 points in the psilocybin group and 6.0 points in the escitalopram group. The difference of -2.0 points did not reach statistical significance (p=0.17), but psilocybin outperformed escitalopram in 14 of 16 secondary endpoints, including well-being, anxiety, anhedonia, and sexual function. Clinically, remission was achieved by 57% of psilocybin patients vs 28% in the escitalopram group.

The significance of this study is substantial. It is the first evidence that a short psychedelic intervention (2 sessions spaced 3 weeks apart) can yield effects comparable to daily pharmacotherapy over 6 weeks. More importantly, the side effect profile was drastically different: escitalopram caused classic SSRI symptoms (nausea, sexual dysfunction, insomnia), while psilocybin generated acute, transient effects on the day of the session.

Goodwin 2022: COMP360 in treatment-resistant depression in NEJM

The phase IIb study by Compass Pathways, published in the New England Journal of Medicine in November 2022, is the largest RCT of psilocybin in treatment-resistant depression (TRD) to date. Guy Goodwin from Oxford led a multicenter study in 10 countries, with a total of 233 patients (NEJM, 2022). Patients had at least 2 failed attempts with antidepressants.

Participants were randomly assigned to three groups: psilocybin 25 mg, 10 mg, or 1 mg (active placebo), in a single session with a psychotherapeutic structure. The primary endpoint MADRS (Montgomery-Asberg Depression Rating Scale) after 3 weeks showed a reduction of 12.0 points in the 25 mg group, 7.9 in the 10 mg group, and 5.4 in the 1 mg group. The difference between 25 mg vs 1 mg was statistically significant (p<0.001), with Cohen's d around 0.9.

29% of patients in the 25 mg group achieved remission after 3 weeks (MADRS <=10), compared to 8% in the 1 mg group. After 12 weeks, 20% of patients in the 25 mg group maintained remission, indicating the need for repeated sessions. Safety: serious adverse events were reported in 9% of patients in the 25 mg group (mainly anxiety episodes and suicidal thoughts), compared to 4% in the placebo group. This data prompted the FDA to grant COMP360 Breakthrough Therapy status.

Davis 2020 and other Johns Hopkins studies in depression

Alan Davis and Roland Griffiths' team at Johns Hopkins published in JAMA Psychiatry in November 2020 an RCT of psilocybin in non-resistant depression (MDD, n=27) (JAMA Psychiatry, 2020). Protocol: 2 sessions of 20-30 mg psilocybin with 11 hours of psychotherapy. Immediate vs delayed treatment group (waiting list).

Results: average GRID-HAMD reduction of 17 points after 8 weeks, 71% of patients achieved a clinical response (>50% reduction), and 54% achieved remission. Gukasyan 2022 in the same group showed maintenance of effect in 75% of patients over 12 months follow-up (Journal of Psychopharmacology, 2022). These are some of the most impressive data in psychiatry in the last decade.

Carhart-Harris 2021 (n=59) in Nature Medicine showed that 2 sessions of 25 mg psilocybin yield effects comparable to 6 weeks of escitalopram in depression (Nature Medicine, 2021). Goodwin 2022 COMP360 in NEJM (n=233) demonstrated a reduction in MADRS by 12 points after a single dose and 29% remission after 3 weeks in treatment-resistant depression (NEJM, 2022).

How does psilocybin support anxiety treatment in cancer patients?

Patients with advanced cancer often experience profound existential anxiety, depression, and demoralization. Two parallel RCTs published together in the Journal of Psychopharmacology in December 2016 (Griffiths Johns Hopkins, n=51 and Ross NYU, n=29) showed that a single session of 22-30 mg psilocybin provides clinically significant reductions in anxiety and depression lasting for 6 months in over 60% of patients (Journal of Psychopharmacology, 2016).

Follow-up by Agin-Liebes 2020 from NYU after 4.5 years showed that 60-80% of patients still reported clinically significant benefits. This is an unprecedented outcome in palliative psychiatry, where traditional antidepressants often lag behind disease progression and have a delayed onset of action of 4-6 weeks, which can be unacceptable for terminal patients.

Why does psilocybin work in existential anxiety?

The hypothesis is as follows: therapeutic dose psilocybin triggers what is known as a "mystical experience" (MEQ-30 score >0.6) in some participants, which includes a sense of unity, transcendent meaning, and reconciliation with reality. Griffiths 2016 demonstrated a strong correlation between the intensity of the mystical experience and long-term improvement in anxiety and depression parameters (r=0.5-0.7).

For cancer patients, it is about confronting finitude and changing the relationship to it, rather than 'curing' an organic disease. Psilocybin does not cure cancer; it changes the psychological approach to dying. In this context, it is one of the few psychiatric interventions with a significant effect in patients with advanced disease.

MDMA, ayahuasca, and the context of other psychedelics

Psilocybin is not the only psychedelic in clinical research. MDMA in the treatment of PTSD has undergone phase III trials by MAPS (Mitchell 2021, 2023) with impressive results: 67% of patients no longer met PTSD criteria after 3 sessions of 80-180 mg MDMA (Nature Medicine, 2023). However, the FDA in August 2024 refused to register MDMA, citing methodological limitations.

Ayahuasca (a mixture of DMT and MAO inhibitors) is being studied in treatment-resistant depression, in the Brazilian RCT Palhano-Fontes 2019 a single dose reduced MADRS by 7 points one week after the session (Psychological Medicine, 2019). Ketamine and esketamine (Spravato) are the only registered 'psychedelic-adjacent' drugs for treatment-resistant depression in the European Union since 2019.

Griffiths 2016 (Johns Hopkins, n=51) and Ross 2016 (NYU, n=29) showed that a single session of psilocybin 22-30 mg results in a reduction of anxiety and depression in >60% of cancer patients lasting for 6 months (Journal of Psychopharmacology, 2016). The effect correlates with the intensity of the mystical experience MEQ-30. Follow-up after 4.5 years: 60-80% of patients still report clinical benefit.

What is the set-setting-integration protocol in psilocybin therapy?

Set-setting-integration is a three-phase clinical model developed by Timothy Leary in the 1960s and updated by Bill Richards and Roland Griffiths at Johns Hopkins. At the Johns Hopkins Center for Psychedelic and Consciousness Research, the standard protocol includes 4-8 hours of preparation, 6-8 hours of dosing session, and 4-8 hours of integration, with the presence of two trained therapists at all times (Johns Hopkins CPCR, 2021). The protocol is not optional.

Each component has a specific clinical function. Set builds psychological safety and clarity of intention. Setting reduces the risk of anxiety reactions and 'bad trips.' Integration translates fleeting insights into lasting behavioral change. Omitting any of these elements invites trauma, not therapeutic effect.

Set: patient mindset and intention

Set encompasses everything the patient brings to the session: mood, expectations, fears, history, health status, stress level. In the Johns Hopkins protocol, the set is built over 2-4 preparatory sessions lasting 60-90 minutes each. In these meetings, therapists discuss with the patient their life narrative, trauma, therapeutic goals, and concerns about the substance itself.

It is also crucial to teach the so-called 'flight instructions': a short list of principles that stabilize during difficult moments of the session. Richard 2016 lists five principles: 'trust, let go, be open' plus breathing techniques and non-verbal signals from therapists. A patient entering a session without this preparation has a significantly higher risk of dysregulation and trauma.

Setting: safe clinical environment

Setting refers to the physical and interpersonal environment of the session. Johns Hopkins recommends: a quiet room with warm lighting, a comfortable bed or chair, an eye mask, headphones with selected music (the standard Johns Hopkins playlist includes 6-8 hours of classical, ambient, and sacred music), the presence of two therapists (at least one woman), ensured sanitary breaks, monitoring of vital parameters.

Why two therapists? For transference dynamics, support possibilities, and safety (both for the patient and the therapist). In the MAPS protocol for PTSD, this principle is a prerequisite. Clinical setting is radically different from recreational context, where the environment is unpredictable and support is incidental. This is the fundamental difference between therapy and self-treatment.

Integration: from insight to behavioral change

Integration is the phase most often underestimated, yet crucial for the durability of the effect. It includes 2-4 psychotherapy sessions within 2-4 weeks after dosing. The goal is to translate mystical, emotional, and cognitive experiences into concrete changes in daily life, relationships, habits, and choices.

Without integration, even a strong psychedelic experience 'fades away' within a few weeks. Watts 2017 in the Journal of Humanistic Psychology described, based on 20 patients with depression, that individuals without structured integration were significantly more prone to symptom relapse within 6 months (Journal of Humanistic Psychology, 2017). Integration is not a luxury; it is part of treatment.

Set-setting-integration is a three-phase clinical protocol developed at the Johns Hopkins Center for Psychedelic and Consciousness Research: 4-8 preparatory sessions, a 6-8 hour dosing session with two therapists, 2-4 integration sessions (Johns Hopkins CPCR, 2021). Omitting any of the elements drastically increases the risk of traumatization and decreases the durability of the therapeutic effect.

Does psilocybin help in treating addictions?

Addictions are the second area where psilocybin has shown impressive results in open trials. Johnson 2017 from Johns Hopkins conducted a pilot study with 15 long-term smokers: after 2-3 sessions of 20-30 mg psilocybin as part of an anti-nicotine protocol, 67% of participants maintained abstinence after 12 months, compared to 35% for standard therapy (Journal of Psychopharmacology, 2017). This is twice as much as with pharmacotherapy using bupropion or varenicline.

The results require confirmation in larger RCTs, but are consistent with the mechanism: psilocybin seems to 'reset' rigid behavioral patterns, including cravings and consumption rituals. Additionally, the mystical experience appears to provide patients with insight and motivation for change that is difficult to achieve through psychotherapy alone.

Alcohol, cocaine, opioids: what data do we have?

Bogenschutz 2022 in JAMA Psychiatry (n=93) showed in an RCT that 2 sessions of 25 mg psilocybin in patients with alcohol use disorder (AUD) resulted in an 83% reduction in heavy drinking days vs 51% in the placebo group after 32 weeks (JAMA Psychiatry, 2022). This is the first large RCT in AUD with psychedelics and the outcome is strongly positive.

For cocaine and opioids, the data is early but promising. Brown 2017 in the Journal of Psychopharmacology described a serial case of 10 opioid-dependent individuals after a psilocybin session with a subsequent 6-month abstinence in 6 of them. RCTs are ongoing at Johns Hopkins and Yale regarding cocaine. MAPS is conducting parallel studies on MDMA in alcohol use disorders, with positive phase II results.

Mechanism: why psychedelics in addictions?

Carhart-Harris's 'pivotal mental states' theory suggests that psychedelics enter the brain in a plasticity state that allows for the restructuring of deeply rooted beliefs and patterns. For an addicted person, where addictive behavior takes the form of a rigid, automatic algorithm, this 'soft' brain is a window for change. But just a window. Without psychotherapy, social support, and environmental changes, the effect will not be sustained.

This clinical model is important because it shows that psilocybin is not a "magic pill," but a tool that opens a certain state in which the patient can work. Like a hammer: useful only for someone who knows what they want to build. The model of "psychotherapy assisted by a psychedelic," rather than "the psychedelic in itself," is now the consensus at Johns Hopkins, Imperial College, and Yale.

Bogenschutz 2022 in JAMA Psychiatry (n=93) showed an 83% reduction in heavy drinking days in patients with AUD vs 51% placebo after 32 weeks (JAMA Psychiatry, 2022). Johnson 2017 at Johns Hopkins achieved 67% nicotine abstinence after 12 months vs 35% for standard therapy (Journal of Psychopharmacology, 2017).

What are the main risks of psilocybin therapy?

Despite impressive effectiveness in selected groups, psilocybin carries specific risks that must be considered before each session. Johnson 2019 in ACS Pharmacology and Translational Science lists seven major risk areas: cardiovascular, psychiatric, drug interactions, neurological, long-term perceptual, behavioral, and legal context (ACS Pharmacology, 2019). None of these are marginal.

Psilocybin risks are varied. There is no potential for addiction, no lethal LD50 (psilocybin has exceptionally low acute toxicity), and no withdrawal syndrome. But there are acute reactions and threats in specific subgroups that need to be clinically recognized before qualifying a patient. This is why the protocol includes 4-8 preparatory sessions.

Risk of triggering psychosis and bipolar disorder

The most serious contraindication is a family or personal history of schizophrenia, schizoaffective disorder, or bipolar disorder. Psilocybin as a 5-HT2A agonist may trigger the first psychotic episode in genetically predisposed individuals. This risk is difficult to quantify because most RCTs exclude these groups. In serial data from Johns Hopkins from 2000-2019, 2 cases were recorded out of about 1200 sessions (ACS Pharmacology, 2019).

For bipolar disorder, psilocybin can trigger a manic or hypomanic episode. In individuals with first-degree relatives with schizophrenia or bipolar disorder, standard clinical protocols exclude such patients. This is not "excessive caution"; it is a strict safety criterion. A person with such a history considering psilocybin should undergo a psychiatric and genealogical consultation before making any decisions.

Interactions with SSRIs, SNRIs, and MAOIs: serotonin syndrome

Psilocin acts on the 5-HT2A receptor. Combining it with drugs that increase serotonin levels in synapses (SSRIs, SNRIs, MAOIs, tramadol, triptans, lithium, some opioids) could theoretically trigger serotonin syndrome. In clinical practice, Johns Hopkins and Compass Pathways require discontinuation of SSRIs/SNRIs for 2-6 weeks before the session (depending on the drug's half-life: fluoxetine with a long half-life requires a longer washout than sertraline).

Additionally, chronic SSRIs can "suppress" the effect of psilocybin through down-regulation of 5-HT2A receptors, as seen in several reports. Gukasyan 2023 in Psychopharmacology described a reduced response in patients with long-term SSRI therapy, with the effect diminishing after 4-6 weeks of washout. MAOIs are an absolute contraindication because they can cause hypertensive crises and serotonin syndrome. Never combine.

Cardiovascular and neurological risks

Psilocybin raises blood pressure by 15-25% and heart rate by 10-20 beats per minute within 60-90 minutes after dosing. For a healthy person, this is safe, but in patients with ischemic heart disease, heart failure, uncontrolled hypertension, the risk of cardiovascular events increases. RCTs exclude patients with IHD, CHF II-IV NYHA, arrhythmias, stroke within 6 months.

A rare but documented complication is HPPD (Hallucinogen Persisting Perception Disorder), which is chronically recurring visual perception disturbances (trailing, halos, afterimages) after the substance's effects have worn off. It occurs in less than 1% of psychedelic users but can persist for years. The risk is higher in individuals with migraine with aura and anxiety disorders.

Challenging experience: "bad trip" and anxiety reactions

In the Carbonaro 2016 study in the Journal of Psychopharmacology, 39% of 1993 psilocybin mushroom users reported at least one "challenging experience" involving intense fear or anxiety. For 11%, this experience was "among the 5 most difficult in life" (Journal of Psychopharmacology, 2016). In clinical settings with therapist support, the frequency of traumatizing reactions dramatically decreases.

This is another argument for the absolute necessity of the set-setting-integration protocol. Self-use of psilocybin in an uncontrolled environment, without a therapist and without preparation, carries a significantly higher risk of traumatization than a clinical session. 30-40% of participants in studies have difficult moments during dosing, but in a clinical context, these moments are processed and integrated into the therapeutic process.

Unique observation: In the Polish debate on psychedelics, three completely different things are often confused. First: recreational use of mushrooms in the park with friends. Second: self-administered "microdosing" at home. Third: structured psilocybin therapy in a clinical hospital with two therapists. Only the third has an evidence base. Mixing these categories in the media creates a false impression that "psilocybin cures depression" as a universal substance, while it is the protocol that heals, and psilocybin is just one of its elements.

The main risks of psilocybin include triggering psychosis in predisposed individuals, serotonin syndrome with SSRIs/SNRIs/MAOIs, an increase in blood pressure and heart rate by 15-25%, and a "challenging experience" in 30-40% of participants (ACS Pharmacology, 2019). Absolute contraindications: family history of SZ or BD, concurrent MAOIs, uncontrolled heart diseases. The set-setting-integration protocol drastically reduces traumatization.

What is synthetic psilocybin and how does it differ from natural psilocybin?

Almost all clinical studies on psilocybin use synthetic substances rather than dried mushrooms. Natural psilocybin in Psilocybe cubensis occurs in concentrations of 0.5-1.2%, accompanied by psilocin, baeocystin, norbaeocystin, and several dozen other tryptamine alkaloids in varying proportions. Dose standardization is impossible without HPLC chromatography. Therefore, all RCTs from Carhart-Harris to COMP360 use GMP-grade synthetic psilocybin.

Synthetic psilocybin is exactly the same chemical compound as psilocybin from mushrooms: O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine. After ingestion, it undergoes the same conversion to psilocin. From a pharmacokinetic and pharmacodynamic perspective, the difference between "mushrooms" and a synthetic "pill" is the difference between a holistic phyto-chemical matrix and an isolated molecule, analogous to morphine versus opium.

COMP360, Usona, Cybin: three companies, three programs

Compass Pathways has been developing COMP360, its proprietary synthetic crystalline polymorph of psilocybin, since 2016. The phase III program in treatment-resistant depression includes multiple centers in the USA and EU, with a report expected in 2026-2027. Usona Institute (non-profit) is conducting parallel research on psilocybin in non-resistant depression (MDD) as part of the Breakthrough Therapy program. Cybin is developing a psilocybin analog, CYB003, which in a phase II study showed comparable efficacy with a shorter duration of effect (about 4 hours vs 6-8).

This differentiation is important. If the FDA registers psilocybin for depression, it will likely be COMP360 or another standardized synthetic form. Mushrooms as a medicinal product are difficult to standardize, GMP production, and quality control. In some states in the USA (Oregon, Colorado), mushrooms are already legal under therapeutic programs, but with strict state oversight.

Australia 2023: the first country with prescriptive psilocybin

In February 2023, the Australian TGA (Therapeutic Goods Administration) made an unprecedented decision, moving psilocybin and MDMA from Schedule 9 (prohibited) to Schedule 8 (prescription drug, controlled) for the treatment of treatment-resistant depression (psilocybin) and PTSD (MDMA). From July 1, 2023, authorized psychiatrists can prescribe psilocybin to patients in the context of structured psychotherapy.

This is the first precedent in the world. The cost of one psilocybin session in Australia is AUD 20,000-30,000, which limits accessibility. The FDA in the USA has not yet registered psilocybin, but granting COMP360 Breakthrough Therapy status in 2018 and 2019 for treatment-resistant and non-resistant depression suggests that registration may occur in 2026-2028.

All key RCTs use GMP synthetic psilocybin (COMP360 Compass Pathways, Usona Institute). Australia is the first country to register psilocybin by prescription for treatment-resistant depression since July 2023 (TGA Australia, 2023). The FDA in the USA is considering registering COMP360 in 2026-2028 based on phase III study results.

What is the legality of psilocybin in Poland in 2026?

Poland has some of the most restrictive regulations in Europe regarding psychedelics. The Act on Counteracting Drug Addiction of July 29, 2005 (Journal of Laws 2005 No. 179 item 1485) classifies psilocybin, psilocin, and psilocybin mushrooms as psychotropic substances in Schedule I-P. Possession, cultivation, trade, and production are punishable (Journal of Laws 2005 No. 179 item 1485). In 2026, there is no registered psilocybin therapy program in Poland, apart from very limited scientific projects.

Penalties in the penal code and law: Article 62 – possession of a small amount – up to 3 years of imprisonment; possession of a significant amount – up to 10 years; Article 63 – cultivation of psilocybin mushrooms – up to 8 years; Article 56 – trafficking in psychotropic substances – up to 12 years. For the Polish reader, this is clear: self-use of psilocybin for "therapeutic" purposes in Poland constitutes a crime and cannot be recommended.

Polish Psychedelic Society and the emerging community

The Polish Psychedelic Society (PTP) is a public benefit organization operating since 2014, bringing together psychiatrists, psychologists, scientists, and journalists interested in psychedelic psychiatry (Polish Psychedelic Society, 2024). PTP conducts educational activities, organizes conferences, translates scientific publications, and supports Polish researchers applying for approvals for clinical studies.

In 2024-2025, the first academic applications for approvals to conduct clinical research with psilocybin in Poland emerged (mainly in Warsaw and Gdańsk centers). The procedures are tedious, requiring the consent of the Minister of Health, the Chief Pharmaceutical Inspector, and the Bioethics Committee. A realistic horizon for the first results from Poland is 2027-2030.

Legally and clinically: what is allowed and what is not?

Allowed: reading, education, participation in conferences, conducting academic research after obtaining approvals, discussing with a psychiatrist one's history and expectations regarding potential psychedelic therapies in the future. It is also allowed to familiarize oneself with clinical protocols and publications in peer-reviewed journals.

It is prohibited: possession of psilocybin in any form, cultivation of Psilocybe mushrooms (including wild-growing Psilocybe semilanceata, which naturally occur in Polish meadows in the fall), trafficking, production, import. "Psilocybin therapy" conducted by an unregistered therapist in Poland in 2026 is a crime, regardless of therapeutic intentions.

What about "trips" to Amsterdam, Jamaica, Portugal?

In the Netherlands, psilocybin is illegal, but "magic truffles" (sclerotia of Psilocybe) are a formally legal product sold in smart shops. Several companies offer psilocybin "retreats" (Synthesis, Psyched2, others). The costs of a 3-7 day program range from 1800 to 3500 euros. This is a gray legal-clinical area: these are not medical therapeutic programs in the sense of EMA, although some use therapeutic language.

Jamaica and Portugal have less restrictive laws. For a Polish citizen, going on such a retreat is not a crime if the substance is consumed where it is legal and does not return to Poland. However, this is also not "medical therapy," and the patient does not have the legal-medical protection that would exist in a registered clinical program. Risk assessment before such a trip requires a psychiatric consultation and thorough due diligence of the given center.

Psilocybin is listed in Poland under Schedule I-P of the Act on Counteracting Drug Addiction of July 29, 2005, with penalties of up to 10 years in prison for possession (Journal of Laws 2005 No. 179 item 1485). In 2026, there are no registered psilocybin therapy programs. The Polish Psychedelic Society conducts educational and scientific activities. The first national RCTs are expected in the horizon of 2027-2030.

What are the legal options for mental health support in Poland?

For individuals struggling with depression, anxiety, or addiction in Poland, where psilocybin therapy remains outside the law, there are legal and well-researched tools. Since 2022, the NFZ has funded psychodynamic, cognitive-behavioral (CBT), and humanistic psychotherapy in Mental Health Clinics. Escitalopram, sertraline, and venlafaxine are the first-line standard in depression. In treatment-resistant depression, esketamine (Spravato) is available in NFZ programs and ketamine off-label in several centers (EMA, 2019).

The second level of support is medical cannabis on prescription (Bedrocan, Tilray, Aurora), available in Poland since 2017 for the treatment of selected indications, including chronic pain, spasticity, chemotherapy-induced emesis. The third level is non-pharmacotherapeutic supplements: CBD oil, CBG, adaptogens (Lion’s Mane, Rhodiola, Ashwagandha). This is not treatment for clinical depression, but legal support for somatic symptoms and subclinical anxiety.

Psychotherapy: CBT, EMDR, ACT, and other approaches with documented effectiveness

Cognitive-behavioral therapy (CBT) is the best-documented form of therapy for depression and anxiety worldwide. A meta-analysis by Cuijpers 2023 in The Lancet Psychiatry (257 RCTs, n=25000) showed an average reduction in the Beck Depression Inventory of 8.6 points after 12-16 sessions, with the effect lasting 12 months in 60% of patients (The Lancet Psychiatry, 2023). The cost in Poland: NFZ for free (with a waiting list of 3-9 months) or privately 150-300 PLN per session.

EMDR (Eye Movement Desensitization and Reprocessing) is very effective in PTSD, comparable to MDMA-assisted therapy in some meta-analyses. ACT (Acceptance and Commitment Therapy) shows a solid evidence base in depression, anxiety, and chronic pain. The choice of method should occur in consultation with a certified psychotherapist, preferably in PTPP (Polish Society of Cognitive-Behavioral Therapy) or PTPD.

Pharmacotherapy SSRIs, SNRIs, ketamine

SSRIs (escitalopram, sertraline, paroxetine) and SNRIs (venlafaxine, duloxetine) are first-line medications for moderate to severe depression. The effect appears in 4-6 weeks, with remission achieved by 30-40% of patients after the first line, and another 20-30% after changing the medication or augmentation. This has a significantly weaker signal than psilocybin in studies but a better-known safety profile and easier outpatient application.

Esketamine (Spravato) in nasal form has been registered in the EU for treatment-resistant depression since 2019. It requires administration in a medical facility under supervision 2 hours after application. Remission after 4 weeks is achieved by 27% of patients, compared to 12% in the placebo group (Daly 2019, JAMA Psychiatry). Ketamine off-label (intravenously, intramuscularly) is available in several Polish centers, with an antidepressant effect within 24-72 hours.

CBD, CBG, and vaporizing dried flowers: when do they make sense?

CBD (cannabidiol) is a non-psychoactive cannabinoid from hemp, legal in Poland, with sublingual bioavailability of 13-19%. Shannon 2019 in the Permanente Journal (n=72) showed a 79% improvement in individuals with anxiety after 25-75 mg of CBD daily over the first 4 weeks (PMC Permanente Journal, 2019). CBD does not treat clinical depression but may reduce subclinical anxiety and improve sleep.

For the Polish reader, a practical option is SOOL Broad Spectrum CBD oil 5% for 76 PLN, where 1 drop is about 2.5 mg of CBD. Start with 5-10 mg in the evening for 2 weeks, then possibly increase to 25-50 mg daily in divided doses. For individuals with higher tension and insomnia, there is SOOL Broad Spectrum CBD Oil 10% for 99 PLN, where 1 drop is about 5 mg of CBD.

CBG (cannabigerol) has a different profile: it acts on 5-HT1A and alpha-2 adrenergic receptors, reported as more "daytime," supporting attention. Cannova CBG oil 15% for 240 PLN provides about 7.5 mg of CBG per drop. For those preferring a faster onset of action in vaporized form, there is Mars CBD 9% flower for 59 PLN, with effective bioavailability of 30-40% through vaporization.

Observation at u Bucha: In our conversations with clients, we notice that people seeking "natural alternatives" to antidepressants often confuse CBD with psychedelics. CBD is not "psilocybin without the law"; it is a different mechanism (endocannabinoid, 5-HT1A, TRPV1). It may support sleep and reduce tension in some individuals, but it does not replace psychotherapy or SSRIs in clinical depression. The best effects are seen in clients who combine CBD with regular therapy, movement, and sleep hygiene.

Legal options for mental health support in Poland: CBT (average reduction in the Beck Depression Inventory of 8.6 points after 12-16 sessions) (The Lancet Psychiatry, 2023), SSRIs/SNRIs, esketamine in treatment-resistant depression (EMA, 2019), CBD 25-75 mg in anxiety (PMC Permanente Journal, 2019). Key: consultation with a psychiatrist before any treatment change.

What is the place of psilocybin microdosing in depression treatment?

Microdosing psilocybin is a separate topic from full-dose therapy. It involves taking 0.1-0.3 g of dried mushrooms (1/10-1/20 of the psychoactive dose), usually every 3 days for 4-8 weeks. Szigeti 2021 in eLife (n=191, Imperial College, self-blind RCT) showed that individuals microdosing psilocybin or LSD and those on placebo reported nearly identical mood improvements after 4 weeks (eLife, 2021). The dominant component is expectations.

This does not mean that the effect does not exist. Placebo in psychiatry accounts for 30-50% of therapeutic response, which is a real clinical change. But as of now, we have no evidence that psilocybin microdosing has a pharmacological effect significantly different from placebo. Proof-of-concept studies are ongoing in Cambridge (BJPsych Open), but results have not yet been published in peer-reviewed form.

Why is microdosing still popular?

The popularity of microdosing has its roots in Silicon Valley culture (Fadiman 2011), reinforced by social media and the subreddit r/microdosing (>280,000 members in 2024), as well as the narrative of a "natural lifestyle hack." Some users report improvements in mood, concentration, and creativity. Rootman 2021 in Scientific Reports collected data from 8,500 users of the Quantified Citizen app, observing improvements in mood but also an increase in neuroticism.

Methodological problem: all large data on microdosing are self-reports without placebo. When a self-blind design was introduced in Szigeti 2021, the placebo vs active difference disappeared. This is consistent with the hypothesis of the dominant expectation effect. This means that the "microdosing protocol" may have value as a disciplinary practice (journal, ritual, intentionality), but the substance itself likely plays a minor role.

Microdosing in treatment-resistant depression: ongoing studies

Cambridge is conducting a proof-of-concept RCT of psilocybin microdosing without psychedelic effects in patients with treatment-resistant depression (BJPsych Open, protocol). The goal is to see if a low dose (below 2 mg of psilocybin) can have an antidepressant effect without inducing a psychedelic experience. Results are expected in 2026-2027.

The theoretical hypothesis is interesting: if the antidepressant mechanism of psilocybin is based on neuroplasticity (BDNF, dendritic spines), then a low dose may be sufficient to induce plasticity without "tripping." Preclinical data from Shao 2021 in Neuron indicate that the neuroplastic effect occurs even at sub-perceptual doses. But this remains a hypothesis. Without human RCTs, we do not know.

For the Polish reader: psilocybin microdosing is illegal

Reminder: in Poland, possession and cultivation of psilocybin mushrooms, even in microdoses, is a crime according to the law of July 29, 2005. A "legal alternative to microdosing" in Poland is CBD or CBG in low doses, Lion’s Mane, Rhodiola. We write more about this in our guide. Microdosing / mikrodawkowanie.

Szigeti 2021 in eLife (Imperial College, n=191, self-blind RCT) showed that the effect of psilocybin microdosing is statistically indistinguishable from placebo after 4 weeks (eLife, 2021). The dominant component is expectations and ritualization. Proof-of-concept RCTs are ongoing in Cambridge on sub-perceptual psilocybin in treatment-resistant depression, with results expected in 2026-2027.

What next for psilocybin? Horizon 2026-2030

The coming years will be decisive for the place of psilocybin in psychiatry. Expected milestones include the results of phase III COMP360 (2026-2027), FDA registration (likely 2027-2028), EMA evaluation, and the first reimbursement programs in selected EU countries (2028-2030). Compass Pathways already has 3 completed phase II trials and 2 ongoing phase III trials with a total of over 1000 patients (Compass Pathways, 2024).

For patients and doctors, this means that psilocybin may enter mainstream psychiatry within 3-5 years, at least in the USA, Australia, Switzerland, and Germany. For Poland, the horizon is further away due to restrictive laws and lack of clinical programs. Realistically: 2030-2035 is the minimum for any regulatory changes in Poland.

Challenges: cost, accessibility, scalability

One therapeutic session with psilocybin requires 15-20 hours of work from two therapists, plus a supervising doctor. Estimated cost: 15,000-25,000 dollars for a full cycle (preparation + 2 dosing sessions + integration). This drastically limits accessibility, especially in public health systems. Australia shows that cost is a barrier to mass adoption despite registration.

Attempts to scale are emerging: group therapy (2-6 patients and 2-3 therapists), shortened sessions (CYB003 4 hours instead of 6-8), virtual support in integration. Each of these models has a compromise between cost and effectiveness. The classic Johns Hopkins protocol is the "gold standard," but economically unscalable.

New areas of research: PTSD, OCD, eating disorders

Areas beyond depression where psilocybin research is ongoing include obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), anorexia nervosa, early-stage Alzheimer's disease, cluster migraines, and demoralization in terminal patients. The first pilot studies by Moreno 2006, Sessa 2015, and others show signals in OCD, but larger RCTs are needed.

Peck 2023 in Nature Medicine is conducting an RCT on psilocybin in anorexia nervosa (n=10 pilot). This is a particularly interesting area because anorexia has a very high mortality rate (5-20%) and poor effectiveness of existing therapies. If psilocybin shows a signal, it will be an important proof of concept for "rigid" behavioral and cognitive disorders.

Gabor Mate, trauma, and the role of cultural context

Gabor Mate, a Canadian physician of Hungarian descent, is one of the most well-known promoters of trauma therapy with elements of psychedelics. His model of "compassionate inquiry" integrates traditional psychotherapy with occasional use of ayahuasca or psilocybin in an appropriate legal context. The film "The Wisdom of Trauma" (2021) popularized his approach among Polish readers (The Wisdom of Trauma, 2021).

Mate's role shows a broader context: psychedelic therapy is not just a medical tool but also a cultural one. The framework in which trauma is understood as a result of disrupted relationships, rather than just symptoms, is complementary to the pharmacological approach. This perspective is particularly important in a country like Poland, where transgenerational trauma (World War II, PRL) is strongly present, though poorly articulated clinically.

Horizon 2026-2030 for psilocybin: results of phase III COMP360 (2026-2027), likely FDA registration (2027-2028), reimbursement programs in the EU (2028-2030) (Compass Pathways, 2024). In Poland, realistic regulatory changes are not expected before 2030-2035. New areas of research: OCD, PTSD, anorexia nervosa, cluster migraines.

Summary: what should we know about psilocybin in psychotherapy?

Conclusions from the last two decades are consistent but nuanced. First, psilocybin-assisted therapy in treatment-resistant depression has strong clinical evidence (Carhart-Harris 2021 Nature Medicine, Goodwin 2022 NEJM, Davis 2020 JAMA Psychiatry) with an effect 2-3 times greater than traditional SSRIs. Second, psilocybin is not a "magic pill": the effect critically depends on the protocol of set-setting-integration and the presence of trained therapists.

Third, the risks are real and varied: triggering psychosis in predisposed individuals, serotonin syndrome with SSRIs/SNRIs/MAOIs, increased blood pressure and heart rate, challenging experiences in 30-40% of participants. Absolute contraindications include family history of schizophrenia and BD. Self-use without a protocol carries a significantly higher risk of traumatization than a clinical session.

Fourth, in Poland, psilocybin is illegal (Schedule I-P, up to 10 years in prison), and registered therapeutic programs do not exist. The first Polish RCTs are expected in 2027-2030. For the Polish patient with depression or anxiety today, reasonable legal paths include: CBT psychotherapy, EMDR, ACT, pharmacotherapy with SSRIs and SNRIs, esketamine in treatment-resistant depression, medical marijuana, and CBD as symptomatic support.

Fifth, microdosing psilocybin is as illegal in Poland as full doses, and its effectiveness in depression remains unconfirmed in rigorous RCTs (Szigeti 2021 showed a dominant placebo effect). Legal equivalents are CBD and CBG in low doses, Lion’s Mane, Rhodiola. These are not substitutes for psilocybin, but legitimate tools for supporting subclinical anxiety and sleep.

Practical recommendation: if you are struggling with depression, anxiety, or addiction, start with a psychiatric consultation. Consider CBT, EMDR, or ACT psychotherapy. If pharmacotherapy is indicated, SSRIs and SNRIs are the first line. In treatment-resistant depression, it is worth discussing esketamine. CBD and CBG may be adjuncts, not substitutes. Keep an eye on clinical research on psilocybin, as the prospect of registration is approaching, though not yet in Poland.

Psychedelics are one of the most promising directions in psychiatry in the last decade, but they are not a panacea and do not solve systemic mental health issues in Poland, such as the shortage of psychiatrists, long waiting lists for NFZ, or low availability of psychotherapy. Real progress requires multi-faceted work: legislative, clinical, educational. Psilocybin may be part of the solution, but it will not replace the entire puzzle.

Frequently Asked Questions

Is psilocybin in psychotherapy legal in Poland?

No. Psilocybin and psilocin are classified as psychotropic substances in Poland under Schedule I-P of the Act on Counteracting Drug Addiction of July 29, 2005 (Journal of Laws 2005 No. 179 item 1485). Their possession, cultivation of psilocybin mushrooms, and trade are punishable by up to 10 years in prison. In 2026, there is no registered psilocybin-assisted therapy program in Poland, even in clinical trials outside of strictly limited scientific projects.

What are the most important findings from clinical studies on psilocybin in depression?

Carhart-Harris 2021 in Nature Medicine (n=59) showed that 2 sessions of 25 mg psilocybin spaced 3 weeks apart were at least equivalent to 6 weeks of escitalopram therapy in treatment-resistant depression (Nature Medicine, 2021). Goodwin 2022 in the New England Journal of Medicine (n=233) demonstrated that a single dose of 25 mg COMP360 reduced the MADRS scale by 12 points vs 5.4 in placebo, and 29% of patients achieved remission after 3 weeks.

How does psilocybin affect the brain and why does it help in depression?

Psilocybin is dephosphorylated to psilocin, which acts as a partial agonist of the 5-HT2A receptor in the cerebral cortex, particularly in the default mode network (DMN). Carhart-Harris 2017 in Scientific Reports showed a decrease in DMN activity correlating with a reduction in depressive rumination (Scientific Reports, 2017). Psilocybin stimulates synaptic neuroplasticity in animal models (Shao 2021, Neuron), increases BDNF, and creates new dendritic connections.

What is the set-setting-integration protocol in psilocybin therapy?

Set-setting-integration is a three-phase clinical model developed by Timothy Leary in the 1960s and updated by the Johns Hopkins team (Griffiths, Richards). Set is the mental attitude and intention of the patient. Setting is a safe environment: a quiet room, an eye mask, selected music, and a present therapist. Integration involves 2-4 psychotherapy sessions after the experience, translating insight into behavioral change (Johns Hopkins CPCR, 2021). Johns Hopkins treats this triad as an essential condition for safety and effectiveness.

What are the risks of psilocybin in psychotherapy?

The main risks are: triggering psychosis in individuals with a family history of schizophrenia or bipolar disorder, serotonin syndrome with interactions with SSRIs/SNRIs/MAOIs (requiring discontinuation of medications for 2-6 weeks before the session), increased blood pressure and heart rate by 15-25% during the session, transient anxiety reactions in 30-40% of participants (Journal of Psychopharmacology, 2016), and the rare risk of HPPD (Hallucinogen Persisting Perception Disorder).

Is microdosing psilocybin effective in depression?

The evidence is weak. The largest self-blind RCT by Szigeti 2021 (Imperial College, n=191) showed that individuals microdosing psilocybin and those on placebo reported nearly identical mood improvements after 4 weeks (eLife, 2021). Proof-of-concept studies on low doses in treatment-resistant depression are ongoing (Cambridge, BJPsych Open), but their results have not yet been published in peer-reviewed form. The dominant effect seems to be psychological.

What are the legal alternatives for those interested in mental health support in Poland?

Legal support in Poland for anxiety states, sleep disorders, and tension includes psychotherapy (CBT, EMDR, ACT), pharmacotherapy with SSRIs and SNRIs after psychiatric consultation, ketamine in prescription treatment programs for treatment-resistant depression, medical marijuana by prescription, and additionally CBD and CBG oil in low doses. CBD at doses of 25-75 mg daily has been studied in social anxiety (Permanente Journal, 2019), and WHO assesses them as safe with no potential for addiction.

What is the difference between psilocybin therapy and regular mushroom consumption?

Psilocybin-assisted therapy (PAP) is a structured protocol: 4-8 preparatory sessions, 1-2 sessions with a therapeutic dose of 20-25 mg, integration sessions, the presence of two therapists, defined music, continuous monitoring of vital parameters. Recreational or self-use of mushrooms does not provide this structure, increases the risk of challenging experiences, traumatization, and triggering psychosis. A meta-analysis by Leger 2022 in the Journal of Psychopharmacology shows that the safety of PAP critically depends on the protocol (Journal of Psychopharmacology, 2022).

This article is purely scientific and educational in nature and does not constitute medical advice. It does not promote or encourage the use of psilocybin, psilocybin mushrooms, or other legally controlled substances in Poland. Psilocybin is illegal in Poland according to the Act on Counteracting Drug Addiction of July 29, 2005 (Journal of Laws 2005 No. 179 item 1485), and its possession, cultivation, and trade are punishable by up to 10 years in prison. Never use psilocybin alone. There is particular risk for individuals with a family or personal history of psychosis, schizophrenia, bipolar disorder, as well as for those taking SSRIs, SNRIs, or MAOIs (risk of serotonin syndrome). Before starting any treatment for depression, anxiety, or addictions, consult a psychiatrist. CBD, CBG, and other supplements do not replace psychiatric treatment.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 24, 2026
Last update: April 24, 2026